Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, July 19th. Stockholders of record on Tuesday, August 13th will be given a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.75%. The ex-dividend date is Monday, August 12th. View Allergan's Dividend History.

Allergan declared that its board has initiated a share buyback plan on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

Allergan plc (NYSE:AGN) released its quarterly earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $4.34 by $0.04. The business had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. Allergan's revenue was down .8% compared to the same quarter last year. During the same period last year, the firm posted $4.42 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 brokerages have issued 1 year price objectives for Allergan's stock. Their predictions range from $144.95 to $255.00. On average, they expect Allergan's share price to reach $179.15 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News headlines about AGN stock have been trending negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Allergan.

Allergan saw a increase in short interest in September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average trading volume of 3,600,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 3.2% of the shares of the company are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Metropolis Capital Ltd (0.05%), State of Alaska Department of Revenue (0.02%), Havens Advisors LLC (0.02%), Alpine Group USVI LLC (0.01%), Gibraltar Capital Management Inc. (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Metropolis Capital Ltd, Nelson Van Denburg & Campbell Wealth Management Group LLC, Gofen & Glossberg LLC IL, Welch & Forbes LLC, Arden Trust Co, Gibraltar Capital Management Inc., Crossmark Global Holdings Inc. and Bremer Bank National Association. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC, Cerebellum GP LLC, Legacy Private Trust Co., Clarus Wealth Advisors and Berkshire Asset Management LLC PA. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $168.94.

Allergan has a market capitalization of $55.42 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]